
3 | Annual Report 2022 Vicore Pharma Holding AB (publ)
Vicore
in Brief
Vicore is a clinical-stage pharmaceutical company focused on severe lung
diseases and related indications.
V
icore is an innovative Swedish
clinical-stage pharmaceutical
company dedicated to creating
life-changing treatments in diseases
where the angiotensin II type 2 receptor
(AT2 receptor) has a central role in
stopping and reversing disease pathol-
ogy. The company is establishing a
portfolio in rare lung diseases including
idiopathic pulmonary fibrosis (IPF) and
pulmonary arterial hypertension (PAH).
C21 is a first-in-class orally available
small molecule angiotensin II type 2
receptor agonist (ATRAG). Almee™ (an
investigational medical device in clinical
development) is a digital therapeutic
(DTx) based on cognitive behavioral
therapy (CBT) created to address the
psychological impact of living with
pulmonary fibrosis. Inhaled IMID is a
new formulation and delivery route of
thalidomide targeting the severe cough
associated with IPF. With our unique
expertise in the ATRAG biology we fuel
our pipeline with several new assets for
a variety of diseases, some of which
could be partnered while others could
be taken to the market by Vicore.
The company’s shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see
www.vicorepharma.com.
Vicore pipeline
Indication Program Preclinical Phase 1 Phase 2 Phase 3 Comments
IPF C21 Final data phase 2a, Q4 2023. Phase 2b trial preparations during 2023
PAH C21 Proof-of-principle study on endothelial function planned during 2023
PF anxiety Almee™ DTx Read-out pivotal study in Q4 2023
IPF cough Inhaled IMID Preclinical formulation
Cardiorenal C106 Phase 1 data, H1 2023
Multiple
indications
C103, C111,
C112
Preclinical studies
Additional
market potential
(untreated patients)
$2.8 Bn
(1)
Current
market
$4.2 Bn
(2)
There is a high unmet need for effective
treatments in IPF today and a large share of the
patients remain untreated or undertreated due
to the side effects of current treatments.
IPF market
1. Estimated based on ~40% of IPF patients currently not on treatment
2. Combined sales of Ofev and Esbriet where Ofev sales since 2019 includes the indication SSc-ILD. Source: Evaluate Pharma